Dag Trader schreef op 22 december 2020 22:29:
dit jaar nog(?):
- EAT COVID – Efti mono, Phase II in COVID-19, start Q4 2020
Investigator-initiated trial evaluating efti in hospitalised COVID-19 patients, Randomized, placebo controlled, University Hospital Pilsen, Czech Republic. Up to 110 patients, 15 day Primary endpoint is patient’s clinical status at day 15(WHO recommended).
And then in the next year, there's quite a lot to expect.
- Relatlimab, Q1 2021 Phase III readout(Relatlimab (development code BMS-986016) is a monoclonal antibody designed for the treatment of melanoma., is een studie van Bristol-Myers Squibb, bedrijf met 26 miljard $ omzet))
- GlaxoSmithKline, you know that we have an exclusive worldwide licensing arrangement there, they expect clinical proof of concept in first half of 2021.
- We will report data from Eftilagimod, our lead program, start of new clinical trials,
- more data from the existing clinical trials,
- also we hope for updates from Novartis
- our preclinical asset IMP-761 should move forward.